PFE Pfizer
- 27.410
- +0.430+1.59%
- 27.420
- +0.010+0.04%
Pfizer News
Pfizer Options Spot-On: On June 18th, 167.51K Contracts Were Traded, With 3.14 Million Open Interest
On June 18th ET, $Pfizer(PFE.US)$ had active options trading, with a total trading volume of 167.51K options for the day, of which put options accounted for 58.18% of the total transactions, and call
GeoVax Stock Rockets 50% on BARDA Award for COVID-19 Vaccine
Pfizer Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/17/2024 67.1% Cantor Fitzgerald $45 → $45 Reiterates Overweight → Overweight 05/02/2024 7.69% Morgan St
Palantir, Oracle, Pfizer CEOs Lobby US Senators on Israel, Hostages
Merck Prepares to Take on Pfizer After Pneumococcal Vaccine Approval -- Barrons.com
By Josh Nathan-Kazis The Food and Drug Administration approval of Merck's new pneumococcal vaccine tees up a new challenge to one of Pfizer's most important products. Pfizer currently dominates the
Day One in Licensing Pact With MabCare for Cancer Therapy
MSD Competes With Pfizer in Pneumococcal Vaccine Market After FDA Approval
Better High-Yield Dividend Stock: Pfizer Vs. Bristol Myers Squibb
Pfizer Invites Public to View and Listen to Webcast of July 30 Conference Call With Analysts
Pfizer Inc. (NYSE:PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:30 a.m. EDT on Tuesday, July 30, 2024. The purpose of the call is to
Merck's (MRK) 21-Valent Pneumococcal Jab Gets FDA Approval
Merck Wins FDA OK for Vaccine Rival to Pfizer's Pneumococcal Shot
FDA Approves Merck's Pneumococcal Vaccine As First Shot Designed For Adults
Monday, the FDA approved Merck & Co Inc's (NYSE: MRK) Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) to protect against 21 strains of bacteria to prevent a severe form of pneumococcal disease.It
Cantor Fitzgerald Maintains Pfizer(PFE.US) With Buy Rating, Maintains Target Price $45
Cantor Fitzgerald analyst Louise Chen maintains $Pfizer(PFE.US)$ with a buy rating, and maintains the target price at $45.According to TipRanks data, the analyst has a success rate of 39.7% and a tota
Pfizer's Setback in Duchenne Muscular Dystrophy Treatment Trial Clears Path for Sarepta, and Many Other Pharma Companies | DelveInsight
Duchenne muscular dystrophy is the most prevalent type of muscular dystrophy found in children. This genetic condition leads to ongoing muscle...
Merck Wins US Approval for Pneumonia Vaccine to Rival Pfizer's
Merck's Vaccine Approval Poses Threat to One of Pfizer's Top-selling Products
By Eleanor Laise Merck's shot, designed to protect against pneumonia and other bacterial infections, is set to compete with Pfizer's Prevnar 20 Merck & Co. Inc. on Monday gained U.S. regulatory appr
Pfizer Options Spot-On: On June 17th, 141.53K Contracts Were Traded, With 3.17 Million Open Interest
On June 17th ET, $Pfizer(PFE.US)$ had active options trading, with a total trading volume of 141.53K options for the day, of which put options accounted for 38.73% of the total transactions, and call
Cantor Fitzgerald Reiterates Overweight on Pfizer, Maintains $45 Price Target
Cantor Fitzgerald analyst Louise Chen reiterates Pfizer (NYSE:PFE) with a Overweight and maintains $45 price target.
Why Is Pfizer Partner BioNTech Stock Trading Lower On Monday?
BioNTech SE's (NASDAQ:BNTX) partner MediLink Therapeutics (Suzhou) Co., Ltd says the FDA has placed a partial clinical hold on the Phase 1 trial.The MediLink-sponsored trial evaluates the early-stage
Express News | 'Kansas Sues Pfizer Over 'Misrepresentations' and 'Adverse Affects' of COVID-19 Vaccine' - Fox Business
Analysis
Price Target
No Data
